Larry Wants More! Ellison's Growing Bet on Oxford Nanopore

Larry Ellison Increases His Stake in Oxford Nanopore

Tech billionaire Larry Ellison, the co-founder and CTO of Oracle, is making an even bigger bet on Oxford Nanopore Technologies. Through EIT Oxford Holdings, an investment arm tied to the Ellison Institute of Technology (EIT) and The University of Oxford, Ellison has raised his stake in the company from 8% to 9%.

Ellison’s investment journey in Oxford Nanopore started in August 2023, when his firm disclosed an initial 3% stake. Since then, his involvement has steadily grown, reflecting his confidence in Oxford Nanopore’s potential in genomics and biotechnology. Notably, Oracle itself also holds a 3.7% stake in Oxford Nanopore, acquired during the company’s initial public offering (IPO).

Market Reactions: Bulls vs. Bears

While Ellison continues to increase his position, short sellers are betting against the stock. Hedge funds such as Millennium and Qube Research have raised their short positions, indicating market skepticism about the company’s valuation and long-term profitability. The battle between bullish insiders like Ellison and bearish short sellers is shaping up to be one of the most intriguing market dynamics for Oxford Nanopore investors.

Why is Ellison So Bullish on Oxford Nanopore?

Ellison’s growing investment underscores his belief in Oxford Nanopore’s leadership in the DNA sequencing industry. The company specializes in nanopore-based genomic sequencing technology, which enables more flexible, scalable, and cost-effective sequencing than traditional methods.

1. A Bet on the Future of Genomics

The genomics market is expected to grow significantly, driven by breakthroughs in healthcare, personalized medicine, drug discovery, and AI-driven biotech innovations. Oxford Nanopore is well-positioned to benefit from these trends, particularly as AI and machine learning advance the interpretation of genetic data.

2. The Ellison Institute’s Vision

The Ellison Institute of Technology (EIT) focuses on health, AI, and sustainability, making Oxford Nanopore a natural fit for Ellison’s broader investment strategy. The firm is betting that nanopore sequencing will play a crucial role in cancer research, infectious disease control, and bioinformatics advancements.

3. Oracle’s Strategic Interest

With Oracle’s 3.7% stake in Oxford Nanopore, there is also speculation that the two companies may explore synergies in cloud computing, data processing, and AI-driven genomic analytics. Oracle’s expertise in big data and AI could complement Oxford Nanopore’s vast genomic datasets, offering significant opportunities in bioinformatics and precision medicine.

The Short Seller Argument: Why Are Some Betting Against Oxford Nanopore?

Despite Ellison’s increasing stake, short sellers are growing more confident in their bearish bets. Millennium and Qube Research are among the major funds increasing their short positions, suggesting concerns about:

1. High Valuation & Market Sentiment

Oxford Nanopore’s stock price may be seen as overvalued compared to its revenue growth. Short sellers believe that investor enthusiasm around genomics and biotech could lead to an overheated valuation, making the stock vulnerable to corrections.

2. Financial Uncertainty & Profitability Challenges

Although Oxford Nanopore is an innovative leader, it remains in growth mode and has yet to achieve consistent profitability. Short sellers argue that the company burns cash too quickly and may face challenges in scaling up its revenue to justify its valuation.

3. Expired Anti-Takeover Provisions

With CEO Gordon Sanghera’s anti-takeover provision expired, Oxford Nanopore could become a target for acquisition or activist investor pressure. Short sellers believe this uncertainty could add volatility to the stock price.

The Next Big Catalyst: Oxford Nanopore’s Upcoming Earnings Report

Investors will be watching Oxford Nanopore’s next earnings report closely, as it could be a pivotal moment for the stock. Key factors to watch include:

Revenue growth and profitability trends
New commercial partnerships and research developments
Potential updates on Oracle’s involvement and future collaborations

A strong earnings report could validate Ellison’s bullish outlook and push short sellers to cover their positions. Conversely, weak financials could embolden the bears and lead to further downside pressure.

What This Means for Investors

1. Is Oxford Nanopore a Good Buy?

For long-term investors, Ellison’s continued stake increase signals strong insider confidence. His investment suggests that Oxford Nanopore’s technology and market position remain attractive for those with a multi-year horizon.

However, short-term volatility could persist due to the growing short interest and uncertainty around financial performance.

2. Should Investors Worry About Short Sellers?

Short seller activity should not be ignored, but it does not necessarily mean the company is in trouble. Often, high short interest can lead to a short squeeze if positive news forces bearish investors to buy back shares at higher prices.

3. Could Oxford Nanopore Become an Acquisition Target?

With Sanghera’s anti-takeover provision expired, Oxford Nanopore could attract interest from larger biotech firms or private equity groups. If a takeover bid emerges, it could significantly boost the stock price in the short term.

Conclusion: Larry Wants More—Should You?

Larry Ellison’s increased stake in Oxford Nanopore sends a strong bullish signal about the company’s long-term potential in genomics and biotech. His investment aligns with the broader trend of AI-driven advancements in healthcare and biotechnology.

However, the rising short interest highlights ongoing market skepticism, making Oxford Nanopore a high-risk, high-reward opportunity for investors.

With an upcoming earnings report, potential acquisition interest, and strategic collaborations on the horizon, Oxford Nanopore’s next chapter will be crucial in determining whether Ellison’s big bet pays off.

For more insights and analysis on Oxford Nanopore, visit Curation Connect.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always consult a qualified professional for guidance related to your specific investment needs.

‍

Disclaimer information

THIS ARTICLE DOES NOT CONSTITUTE ANY FORM OF ADVICE OR RECOMMENDATION AND IS NOT INTENDED TO BE RELIED UPON IN MAKING ANY INVESTMENT DECISIONS. Curation Connect is an information service provided by Curation Corporation. Liability Your investments are your responsibility. No liability whatsoever is accepted by Curation Corporation Limited or any Curation Corporation company of their respective directors, officers, employees or analysts for any loss, whether direct, indirect, special, incidental or consequential, arising whether directly or indirectly as a result of the recipient acting or not acting on any information in any Curation Connect publication, including, without limitation, lost profits arising from the use of the Curation Connect service or any of its publications. We have no liability for any loss of profit, loss of revenue, loss of business, business interruption, loss of opportunity or any indirect, special or consequential loss; any losses which arise from any event beyond our reasonable control; any losses which could not reasonably have been anticipated; or your inability to access and/or use the Curation Connect service or the website. We do not exclude or limit in any way our liability to you where it would be unlawful to do so. Disclaimer Curation Connect publications are provided for general information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument or investment. This report is intended only for investors who are 'professional clients' as defined by the FCA, and may not, therefore, be redistributed to other classes of investors. This document is provided for information purposes only and should not be regarded as an offer, solicitation, invitation, inducement or recommendation relating to the subscription, purchase or sale of any security or other financial instrument. This document does not constitute, and should not be interpreted as, investment advice. You must carry out your own independent research and obtain suitable professional advice before making any investment decision. The Curation Connect publications do not take the specific needs, investment objectives and financial situation of any particular individual into consideration and we cannot state whether any investment mentioned is suitable for you. You should not base any investment decision solely on the basis of the information we publish or provide to you. Always be aware of market risks – never invest money you cannot afford to lose. All investments can go down as well as up. Investing in securities entails risks. Potential Conflicts of Interest Curation Connect or its respective directors, officers, employees, contributors and clients may have or take positions in the securities, entities or investments mentioned in the Curation Connect publications. Any of these circumstances could create, or be perceived as creating, conflicts of interest. Privacy and Registration All information received from you and your use of the Curation Connect service and the website will be used by Curation Corporation Limited in accordance with our Privacy Policy. Please read this for details of how we may process your personal data. On registration for the Curation Connect service, you must provide us with accurate, complete registration information and it is your responsibility to update and maintain changes to your information. Curation Connect, a trading name of Curation Corporation Limited, is entitled to rely on any information you provide to us. Read our full T&Cs, disclaimersand privacy notice. Contact us at info@curationcorp.com Curation Corporation Limited, 58 Borough High Street, London, SE1 1XF, UK